Dyax Announces Antibody Discovery Collaboration with Biogen Idec
Biogen Idec retains rights to develop and commercialize antibodies identified in the collaboration, and Dyax will receive development milestone payments, as well as royalty payments upon successful commercialization by Biogen Idec of products based on antibodies identified by Dyax. Biogen Idec is focused on creating new standards of care in neurology, oncology and immunology.
"I'm very pleased to enter into this collaboration with Biogen Idec, and believe that Dyax's state-of-the-art libraries and high throughput screening technology will provide rapid results, to the benefit of both companies," remarked Henry E. Blair, Chairman, President and CEO of Dyax Corp.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous